

September 16, 2025

To,

**Department of Corporate Relationship
BSE Ltd.**

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001.
Scrip Code: 539177

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol – AIIIL

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”)

With reference to the above subject, we wish to inform that the Company has entered into an Investment Agreement dated September 15, 2025

(“**Agreement**”) with inter alia Serovia Pharma Private Limited (“**Serovia Pharma**”), recording the terms and conditions for inter alia:

- (a) Serovia Pharma issuing and offering and the Company subscribing to 18,95,053 partly paid-up compulsorily convertible preference shares of Serovia Pharma (“**Series B CCPS**”), constituting [3%] (three percent) of the expanded share capital of Serovia Pharma, as determined on fully diluted basis, subject to and in accordance with the terms and conditions of the Agreement; and
- (b) their mutual understanding as to the operation, management, and governance of the Serovia Pharma and their *inter se* relationship as shareholders of the Serovia Pharma and other matters set out therein

The consummation of the transactions contemplated the Agreement is subject to satisfactory fulfilment of certain pre-closing actions recorded in the Agreement, including receipt of the necessary corporate authorizations.

Upon consummation of the transactions contemplated under the Agreement, the Company will hold 3% (three percent) of the expanded share capital of Serovia Pharma, as determined on fully diluted basis, subject to and in accordance with the terms and conditions of the Agreement.

Further, the details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure A**.

Kindly take the same on your records.

Thank you,

For **Authum Investment & Infrastructure Limited**

Amit Dangi
Whole Time Director
DIN: 06527044

Annexure A

Disclosure of information pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Name of the target entity, details in brief such as size, turnover etc.;	<p>Serovia Pharma Private Limited (formerly known as Six Rays Pharma Private Limited), a private limited company incorporated under the provisions of the Companies Act, 2013, having CIN U21001KA2025PTC205529 and having its registered office at Cepha Block 1st Floor, Sy No, 152/6&154/6 Dorasni Palya, Bannerghatta Road, Bangalore - 560076, Karnataka, India (“Serovia Pharma”).</p> <p>Net Worth of Serovia Pharma (as of March 31, 2025): Not applicable as the entity was incorporated on July 19, 2025.</p> <p>Turnover of Serovia Pharma (as of March 31, 2025): Not applicable as the entity was incorporated on July 19, 2025.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
Industry to which the entity being acquired belongs;	<p>Pharmaceutical Industry.</p> <p>Serovia Pharma will be engaged in the business of developing, manufacturing, and distributing pharmaceutical products globally.</p>
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	This acquisition aligns with our long-term strategy of diversifying our portfolio while investing in sectors that demonstrate both stability and growth potential. Our intention is to nurture and expand this business, maximizing value creation for all stakeholders and ensuring a sustainable, profitable future for the Company.
Brief details of any governmental or regulatory approvals required for the acquisition;	No government or regulatory approvals are contemplated to be required for the acquisition. However, consummation of the transaction is subject to satisfactory fulfilment of certain pre-closing actions, including board and shareholder approvals of Serovia Pharma.
Indicative time period for completion of the acquisition;	Subject to completion of pre-closing actions as detailed in the Agreement, the acquisition

	contemplated under the Agreement is expected to be completed by [September 20, 2025].
Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
Cost of acquisition and/or the price at which the shares are acquired;	<p>Primary Infusion of INR 3,000,001,553/- to subscribe to 18,95,053 Series B compulsorily convertible preference shares of Serovia Pharma (“Series B CCPS”) having a face value of INR 10/- (Indian Rupees Ten only), along with a premium of INR 1573.07/- (Indian Rupees One Thousand Five Hundred and Seventy Three and Seven Paise), aggregating to INR 1583.07 (Indian Rupees One Thousand Five Hundred and Eighty Three and Seven Paise) (“Subscription Price”), which shall be payable in the following manner:</p> <p>(a) on application for subscribing to Series B CCPS, an amount equal to 50% of the subscription amount amounting to INR 150,00,00,776.50 /- shall be payable by the Company; and</p> <p>(b) on call being made by the Serovia Pharma in accordance with the terms of the Agreement, the balance 50% subscription amount of INR 150,00,00,776.50/-, shall be payable by the Company.</p>
Percentage of shareholding / control acquired and / or number of shares acquired;	Upon consummation of the transactions contemplated under the Agreement, the Company will hold 3% (three percent) of the expanded share capital of Serovia Pharma, as determined on fully diluted basis, subject to and in accordance with the terms and conditions of the Agreement.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Serovia Pharma will be engaged in the business of developing, manufacturing, and distributing pharmaceutical products globally.</p> <p>Date of Incorporation: July 19, 2025</p> <p>Turnover of last 3 years: Not applicable as the entity was incorporated on July 19, 2025.</p> <p>Country in which Serovia Pharma has presence: India. Serovia Pharma is however intending to expand its presence to Cyprus and US</p>